Novel treatment regimen appears well tolerated, beneficial to children with relapsed brain tumors
The first in-human study of a new immunotherapy that blocks a natural enzyme that tumors commandeer for their protection was well tolerated by children with relapsed brain tumors and enabled many to have unexpected months of a more normal life, researchers say.